BALAXI PHARMACEUTICALS LIMITED (BALAXI) fundamentals
BALAXI PHARMACEUTICALS LIMITED is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BALAXI (ISIN INE618N01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What BALAXI PHARMACEUTICALS LIMITED does
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.
Valuation and market data
| Last close | ₹23.33 |
|---|---|
| Market capitalisation | ₹129 crore |
| Enterprise value | ₹113 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.56 |
| Price to sales (TTM) | 0.45 |
| Book value per share | ₹41.97 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Nov 30 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹273 crore | ₹5 crore | ₹1 crore | 0.00 |
| Mar 2025 | ₹295 crore | ₹29 crore | ₹25 crore | 4.54 |
| Mar 2024 | ₹242 crore | ₹2 crore | ₹-2 crore | -0.46 |
| Mar 2023 | ₹339 crore | ₹57 crore | ₹46 crore | 45.81 |
| Mar 2022 | ₹284 crore | ₹55 crore | ₹48 crore | 47.66 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 66.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.6% |
| Retail and others | 31.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.